Gilead Sciences, Inc. (GILD) is General American Investors Co. Inc.’s 5th Largest Position

General American Investors Co. Inc. held its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 483,600 shares of the biopharmaceutical company’s stock at the end of the second quarter. Gilead Sciences accounts for 3.5% of General American Investors Co. Inc.’s investment portfolio, making the stock its 5th biggest position. General American Investors Co. Inc.’s holdings in Gilead Sciences were worth $34,229,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its stake in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. lifted its stake in shares of Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Gilead Sciences during the 1st quarter worth $143,000. Finally, Crestwood Advisors Group LLC lifted its stake in shares of Gilead Sciences by 11.4% during the 2nd quarter. Crestwood Advisors Group LLC now owns 2,730 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 279 shares during the period. 73.98% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/11/gilead-sciences-inc-gild-is-general-american-investors-co-inc-s-5th-largest-position.html.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 83.04 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock’s 50 day moving average is $81.55 and its 200 day moving average is $71.93. The company has a market cap of $108.44 billion, a PE ratio of 9.02 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the previous year, the firm posted $3.08 EPS. The business’s revenue was down 8.2% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. Gilead Sciences’s payout ratio is 22.58%.

A number of research analysts have weighed in on the company. Morgan Stanley reissued an “equal weight” rating and set a $83.00 price target (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Leerink Swann increased their price target on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research note on Thursday, October 5th. CIBC assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating on the stock. Oppenheimer Holdings, Inc. assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating on the stock. Finally, Jefferies Group LLC assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “positive” rating on the stock. Twelve analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $85.66.

In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares in the company, valued at approximately $8,051,854.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 486,819 shares of company stock worth $39,298,919. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit